Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Company (TAK)
NYSE:TAK
RESEARCH TOOLSreports
Total Valuation
Takeda Pharmaceutical Company has a market cap or net worth of $48.58B. The enterprise value is $77.88B.
Market Cap$48.58B
Enterprise Value$77.88B
Share Statistics
Takeda Pharmaceutical Company has 3,181,943,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,181,943,400
Owned by Insiders―
Owned by Institutions0.83%
Financial Efficiency
Takeda Pharmaceutical Company’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 1.72%.
Return on Equity (ROE)0.02
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)1.72%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee92.97M
Profits Per Employee2.19M
Employee Count49,281
Asset Turnover0.32
Inventory Turnover1.30
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Company is 49.8. Takeda Pharmaceutical Company’s PEG ratio is ―.
PE Ratio49.8
PS Ratio―
PB Ratio―
Price to Fair Value1.03
Price to FCF―
Price to Operating Cash Flow6.41
PEG Ratio―
Income Statement
In the last 12 months, Takeda Pharmaceutical Company had revenue of 4.58T and earned 107.93B in profits. Earnings per share was 34.17.
Revenue4.58T
Gross Profit3.00T
Operating Income342.59B
Pretax Income175.08B
Net Income107.93B
EBITDA1.21T
Earnings Per Share (EPS)34.17
Cash Flow
In the last 12 months, operating cash flow was 1.08T and capital expenditures -218.42B, giving a free cash flow of 861.91B billion.
Operating Cash Flow1.08T
Free Cash Flow861.91B
Free Cash Flow per Share270.88
Dividends & Yields
Takeda Pharmaceutical Company pays an annual dividend of $0.276, resulting in a dividend yield of 3.97%
Dividend Per Share$0.276
Dividend Yield3.97%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.13
52-Week Price Change7.45%
50-Day Moving Average14.81
200-Day Moving Average14.20
Relative Strength Index (RSI)59.87
Average Volume (3m)4.55M
Important Dates
Takeda Pharmaceutical Company upcoming earnings date is Oct 30, 2025, Before Open (Confirmed).
Last Earnings DateJul 29, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend DateMar 31, 2025
Financial Position
Takeda Pharmaceutical Company as a current ratio of 1.01, with Debt / Equity ratio of 65.63%
Current Ratio1.01
Quick Ratio0.52
Debt to Market Cap0.63
Net Debt to EBITDA3.87
Interest Coverage Ratio2.49
Taxes
In the past 12 months, Takeda Pharmaceutical Company has paid 66.94B in taxes.
Income Tax66.94B
Effective Tax Rate0.38
Enterprise Valuation
Takeda Pharmaceutical Company EV to EBITDA ratio is 6.82, with an EV/FCF ratio of 9.65.
EV to Sales1.80
EV to EBITDA6.82
EV to Free Cash Flow9.65
EV to Operating Cash Flow7.81
Balance Sheet
Takeda Pharmaceutical Company has $419.18B in cash and marketable securities with $4.51T in debt, giving a net cash position of $4.09T billion.
Cash & Marketable Securities$419.18B
Total Debt$4.51T
Net Cash$4.09T
Net Cash Per Share$1.28K
Tangible Book Value Per Share-$629.15
Margins
Gross margin is 60.54%, with operating margin of 7.48%, and net profit margin of 2.36%.
Gross Margin60.54%
Operating Margin7.48%
Pretax Margin3.82%
Net Profit Margin2.36%
EBITDA Margin26.42%
EBIT Margin9.80%
Analyst Forecast
The average price target for Takeda Pharmaceutical Company is $17.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$17.00
Price Target Upside11.18% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast1.36%
EPS Growth Forecast-1.81%